Study of Dextromethorphan in OCD and Related Disorders

Description

The purpose of the study is to assess the tolerability and efficacy of dextromethorphan in combination with fluoxetine for symptom relief in OCD and related disorders.

Conditions

Obsessive-Compulsive Disorder, Illness Anxiety Disorder, Body Dysmorphic Disorders, Somatic Symptom Disorder

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of the study is to assess the tolerability and efficacy of dextromethorphan in combination with fluoxetine for symptom relief in OCD and related disorders.

Fluoxetine/Dextromethorphan in Obsessive-Compulsive and Related Disorders: an Open-Label Crossover Pilot Study

Study of Dextromethorphan in OCD and Related Disorders

Condition
Obsessive-Compulsive Disorder
Intervention / Treatment

-

Contacts and Locations

Stanford

Stanford University, Stanford, California, United States, 94304

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Diagnosis of obsessive-compulsive disorder (OCD), body dysmorphic disorder (BDD), illness anxiety disorder (IAD) or somatic symptom disorder (SSD)
  • * Living within California
  • * Capacity to provide informed consent
  • * Current bipolar disorder or psychotic disorder
  • * Active moderate or severe substance use disorder, lifetime severe substance use disorder
  • * Pregnant or nursing women
  • * Use of prescribed psychotropic medications other than fluoxetine for 2 weeks prior to study start
  • * Having commenced OCD-targeted exposure and response-prevention (ExRP) psychotherapy within 2 months of study start

Ages Eligible for Study

18 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Stanford University,

Peter J van Roessel, MD PhD, PRINCIPAL_INVESTIGATOR, Stanford University

Study Record Dates

2025-12-01